Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Ezetimibe108 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00802 | 34960005 | Nutrients | Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial. | 2021 | Details |
| A01605 | 34681219 | Pharmaceuticals (Basel) | Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. | 2021 | Details |
| A01931 | 34558856 | Hepatol Commun | Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04659 | 33549441 | Nutr Metab Cardiovasc Dis | Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. | 2020 | Details |
| A06156 | 32984364 | Front Med (Lausanne) | Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases. | 2020 | Details |
| A06856 | 32720602 | Curr Vasc Pharmacol | Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). | 2021 | Details |
| A07746 | 32366600 | J Pharmacol Exp Ther | Ezetimibe Markedly Reduces Hepatic Triglycerides and Cholesterol in Rats Fed on Fish Oil by Increasing the Expression of Cholesterol Efflux Transporters. | 2020 | Details |
| A08409 | 32123832 | FASEB Bioadv | Identification of hepatic NPC1L1 as an NAFLD risk factor evidenced by ezetimibe-mediated steatosis prevention and recovery. | 2019 | Details |
| A09073 | 31883528 | Lipids Health Dis | Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet. | 2019 | Details |
| A10238 | 31418344 | Curr Vasc Pharmacol | What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? | 2019 | Details |
| A10502 | 31309820 | Curr Vasc Pharmacol | Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. | 2019 | Details |
| A12298 | 30520543 | Cancer Sci | Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. | 2019 | Details |
| A12912 | 30229482 | Hormones (Athens) | Lipids: a personal view of the past decade. | 2018 | Details |
| A13570 | 29903515 | Int J Cardiol | The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. | 2018 | Details |
| A14175 | 29551054 | Korean J Intern Med | Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. | 2018 | Details |
| A14423 | 29413998 | Curr Opin Pharmacol | Lipid-lowering treatment in peripheral artery disease. | 2018 | Details |
| A15777 | 28714405 | Curr Pharm Des | Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter. | 2017 | Details |
| A16175 | 28521870 | Metabolism | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. | 2017 | Details |
| A16662 | 28257594 | Hepatol Res | Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. | 2017 | Details |
| A16796 | 28167864 | J Inflamm (Lond) | Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. | 2017 | Details |
| A16811 | 28159867 | J Lipid Res | Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. | 2017 | Details |
| A16871 | 28116801 | Aliment Pharmacol Ther | Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. | 2017 | Details |
| A17184 | 27923447 | Metabolism | Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice. | 2016 | Details |
| A17486 | 27634173 | Free Radic Biol Med | Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. | 2016 | Details |
| A17490 | 27767079 | Sci Rep | SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy. | 2016 | Details |
| A17515 | 27761360 | FEBS Open Bio | Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates. | 2016 | Details |
| A17614 | 27714510 | Dig Dis Sci | Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. | 2016 | Details |
| A17795 | 27582882 | Therap Adv Gastroenterol | Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. | 2016 | Details |
| A18292 | 27237577 | Metabolism | Non-alcoholic fatty liver disease and dyslipidemia: An update. | 2016 | Details |
| A18583 | 27046953 | Yonago Acta Med | Components of Boiogito Suppress the Progression of Hypercholesterolemia and Fatty Liver Induced by High-Cholesterol Diet in Rats. | 2016 | Details |
| A18806 | 26929777 | Therap Adv Gastroenterol | Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. | 2016 | Details |
| A19157 | 26724391 | Eur J Pharmacol | Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. | 2015 | Details |
| A19411 | 26583037 | Nutr Metab (Lond) | High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs. | 2015 | Details |
| A20133 | 26134926 | Expert Opin Drug Saf | Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? | 2015 | Details |
| A20459 | 25948514 | Eur J Nutr | Modulation of cholesterol-related gene expression by ergosterol and ergosterol-enriched extracts obtained from Agaricus bisporus. | 2015 | Details |
| A20890 | 25659874 | Atheroscler Suppl | The effect of ezetimibe on NAFLD. | 2015 | Details |
| A21090 | 25541989 | PLoS One | LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. | 2014 | Details |
| A21141 | 25520429 | J Lipid Res | Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. | 2014 | Details |
| A21200 | 25482832 | Hepatology | Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). | 2015 | Details |
| A21398 | 25349644 | World J Hepatol | Lipid-lowering agents in the management of nonalcoholic fatty liver disease. | 2014 | Details |
| A21451 | 25310357 | Mol Med Rep | Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice. | 2014 | Details |
| A22294 | 24688217 | J Clin Biochem Nutr | Role of Nrf2 in the alteration of cholesterol and bile acid metabolism-related gene expression by dietary cholesterol in high fat-fed mice. | 2014 | Details |
| A22617 | 24407920 | Diabetologia | The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. | 2014 | Details |
| A22699 | 25796845 | Wiad Lek | [The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. | 2014 | Details |
| A22926 | 24205731 | Nihon Rinsho | [An inhibitor of intestinal cholesterol transporter]. | 2013 | Details |
| A23499 | 23721476 | Hepatol Res | Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease. | 2013 | Details |
| A23519 | 23715726 | Am J Physiol Endocrinol Metab | Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. | 2013 | Details |
| A23720 | 23538201 | J Pharmacol Exp Ther | Ezetimibe increases hepatic iron levels in mice fed a high-fat diet. | 2013 | Details |
| A23753 | 23510093 | Hepatol Res | Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse. | 2013 | Details |
| A23768 | 23500152 | J Hepatol | Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. | 2013 | Details |
| A23906 | 23394094 | Curr Pharm Des | Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? | 2013 | Details |
| A23997 | 23317398 | Curr Pharm Des | Ezetimibe therapy for dyslipidemia: an update. | 2013 | Details |
| A24008 | 23304532 | Int J Hepatol | Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. | 2012 | Details |
| A24307 | 26181068 | Clin J Gastroenterol | Nonalcoholic fatty liver disease: from lipid profile to treatment. | 2012 | Details |
| A24543 | 22770622 | Expert Opin Pharmacother | The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. | 2012 | Details |
| A24655 | 25755424 | J Clin Exp Hepatol | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. | 2012 | Details |
| A24674 | 22617751 | Curr Opin Lipidol | Nonalcoholic fatty liver disease and lipids. | 2012 | Details |
| A24727 | 22554516 | Biochem Biophys Res Commun | Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model. | 2012 | Details |
| A24752 | 22536512 | Int J Hepatol | Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease. | 2012 | Details |
| A25152 | 22132342 | J Lipids | Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. | 2011 | Details |
| A25173 | 22112382 | Drug Metab Dispos | Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. | 2011 | Details |
| A25240 | 22059109 | World J Hepatol | Role of ezetimibe in non-alcoholic fatty liver disease. | 2011 | Details |
| A25299 | 21986643 | Curr Opin Lipidol | Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. | 2011 | Details |
| A25452 | 21817841 | Nihon Shokakibyo Gakkai Zasshi | The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD). | 2011 | Details |
| A26054 | 21160985 | World J Hepatol | Combination drug treatment in patients with non-alcoholic fatty liver disease. | 2010 | Details |
| A26132 | 21044019 | Curr Vasc Pharmacol | Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. | 2011 | Details |
| A26133 | 21044016 | Curr Vasc Pharmacol | Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment. | 2011 | Details |
| A26213 | 20880342 | Diabetes Obes Metab | Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. | 2010 | Details |
| A26316 | 20658156 | J Gastroenterol | Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. | 2010 | Details |
| A26320 | 20654606 | Clin Chim Acta | The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. | 2010 | Details |
| A26356 | 20601094 | Drug Discov Today | Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? | 2010 | Details |
| A26530 | 20355232 | World J Gastroenterol | Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials. | 2010 | Details |
| A26549 | 20222991 | Lipids Health Dis | NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. | 2010 | Details |
| A26591 | 20143458 | World J Gastroenterol | Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? | 2010 | Details |
| A26692 | 19946244 | Med Sci Monit | Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. | 2009 | Details |
| A26878 | 19596472 | J Hepatol | Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. | 2009 | Details |
| A27130 | 21180532 | Therap Adv Gastroenterol | Current status of therapy in nonalcoholic Fatty liver disease. | 2009 | Details |
| A27470 | 18329014 | Eur J Pharmacol | Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. | 2008 | Details |
| A27575 | 18022391 | FEBS Lett | Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. | 2007 | Details |
| A27964 | 16865780 | World J Gastroenterol | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. | 2006 | Details |
| A28603 | 35256232 | Nutr Metab Cardiovasc Dis | Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial. | 2022 | Details |
| A29185 | 34439245 | Cancers (Basel) | Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC. | 2021 | Details |
| A32226 | 28933629 | Autophagy | Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. | 2017 | Details |
| A35109 | 21712950 | Case Rep Gastroenterol | Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities. | 2011 | Details |
| A35509 | 20489159 | Am J Pathol | A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. | 2010 | Details |
| A35538 | 20412324 | Hepatol Res | Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. | 2010 | Details |
| A43554 | 31432115 | Mol Med Rep | Hepatic NPC1L1 overexpression attenuates alcoholic autophagy in mice. | 2019 | Details |
| A43802 | 30840809 | Korean J Intern Med | The utility of ezetimibe therapy in nonalcoholic fatty liver disease. | 2019 | Details |
| A44057 | 30017528 | Int J Cardiol | Improved management of patients after acute coronary syndrome: using nonalcoholic fatty liver disease fibrosis score and ezetimibe? | 2018 | Details |
| A45075 | 26167075 | World J Gastroenterol | Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. | 2015 | Details |
| A45216 | 25635125 | J Lipid Res | The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination. | 2015 | Details |
| A45235 | 25565897 | HIV AIDS (Auckl) | Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. | 2014 | Details |
| A45442 | 24554006 | Diabetologia | Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD? | 2014 | Details |
| A46086 | 21181211 | J Gastroenterol | Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis. | 2010 | Details |
| A46203 | 20385430 | J Hepatol | Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance? | 2010 | Details |
| A46227 | 20185740 | Diabetes Care | Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. | 2010 | Details |
| A46341 | 19443308 | Orv Hetil | [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease]. | 2009 | Details |
| A46391 | 19093209 | Dig Dis Sci | Steatocholecystitis and fatty gallbladder disease. | 2008 | Details |